The latest articles from BioStock
» CombiGene's acquisitions and exit ambitions
» Forendo Pharma enters into agreement with pharmaceutical giant Novartis
» The strategy that will take Toleranzia to an out-licensing agreement
» Loan from Bauerfeind AG signals strong confidence in Xintela
» Aprea Therapeutics shares rise after presentation of new data
» Cancer patients eager to try 2cureX test for individualized treatment
Read BioStock's latest newsletter for week 49 here.
Acquirer of SEK 121 million convertible loan in Karolinska Development An agreement on set-off is entered into. The subscription period in the directed new share issue is extended to December 16. Read more.
AstraZeneca Imfinzi has been approved in China for the treatment of inoperable stage 3 non-small cell lung cancer based on the phase III PACIFIC study. Read more.
AcouBlack receives CE marking for AcouWash which opens up for OEM collaborations and commercialization. Read more.
Smell The rights issue was fully subscribed. Read more.
Orthoma has introduced artificial intelligence in its latest version of Orthoma Treatment Solution. Read more.
Aino Health signs an agreement with Centric regarding the SaaS solution HealthManager. Read more.
Moberg Pharma comments on the results of the North American phase III study with MOB-015. Read more.
Veloxis Pharmaceuticals publishes offer documents and statement from the board. Read more.
News received since yesterday afternoon:
Securities Markets Board noted that the lack of organized trade in Brighter Subscription rights require prior approval. Read moreBrighter, in turn, pointed out that the ongoing issue does not require any prior approval. Read more.
Per-Olof Schrewelius leaves the role as CFO at Alligator Bioscience. Read more.
Dicot has expanded the management team with Jessica Roxhed as new CFO while Gabriela Urquilla will be responsible for external communications as of December 15. Julie Silbers The role of Director of Investor Relations is expanded. Read more.
Vd Fredrik Jonsson has purchased shares in Alteco Medical. Read more.
S2Medical distributor has filed a claim for compensation. Read more.
Colzyx has received SEK 58 million from Horizon 2020. Read more.
AstraZeneca and Daiichi-Sankyo's Trastuzumab deruxtecan achieved a tumor response of 60,9 percent in metastatic HER2-positive breast cancer in a pivotal phase II study. Read more.
Positive preclinical results have been presented in Xintelas glioblastoma project. Read more.
New Chairman of the Board has been appointed in Nicoccino. Read moreThe company is therefore calling an extraordinary general meeting on December 27. Read more.
Asa Riisberg will leave Karo Pharmas board at its own request. Read more.
Enorama Pharma has secured financing through a loan agreement of SEK 17 million and is refinancing an existing loan of SEK 18 million with Swede Unipharma. Read more.
This morning's winner: Doxa 11,7%, AcouSort 7,8%, Xintela 7,1%, Xbrane Biopharma 6,7%, Spago 4,6%
This morning's losers: AlphaHelix -9,7%, Moberg Pharma -8,3%, Raytelligence -8,2%, EURI -7,7%, Vindico -7,2%
Index: OMXS30 -0,10% Healthcare +0,26%
More articles from BioStock